The British Journal of Cardiology, March 2015
—
Cannabis has been employed medicinally and recreationally for thousands of years, but it was not until the 1960s that the structure and pharmacology of its primary phytocannabinoid components, cannabidiol (CBD) and tetrahydrocannabinol (THC) were identified, and another genera…
British Pharmacological Society, July 2010
—
BACKGROUND AND PURPOSE: Cannabidiol (CBD) is a phytocannabinoid, with anti-apoptotic, anti-inflammatory and antioxidant effects and has recently been shown to exert a tissue sparing effect during chronic myocardial ischaemia and reperfusion (I/R). However, it is not known whet…
Seminars in Immunopathology, June 2009
—
Endocannabinoids are endogenous bioactive lipid mediators present both in the brain and various peripheral tissues, which exert their biological effects via interaction with specific G-protein-coupled cannabinoid receptors, the CB(1) and CB(2). Pathological overactivation of t…
Handbook of Experimental Pharmacology, 2005
—
Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in…
The Journal of Clinical Pharmacology, November 2002
—
Marijuana and delta9-tetrahydrocannabinol (THC) increase heart rate, slightly increase supine blood pressure, and on occasion produce marked orthostatic hypotension. Cardiovascular effects in animals are different, with bradycardia and hypotension the most typical response. Ca…